Live Breaking News & Updates on Corticosteroid free remission through

Stay updated with breaking news from Corticosteroid free remission through. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Guselkumab Demonstrates Long-Term Benefit for Crohn Disease

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response. ....

Jan-wehkamp , Anita-afzali , Uc-health-anita-afzali , Johnson , University-of-cincinnati-college-medicine , Johnson-innovative-medicines , United-european-gastroenterology-week , Cincinnati-college , Johnson-innovative , Severely-active-crohn , Participants-with-moderately , Achieved-clinical-remission

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou. ....

United-states , Japan , Calgary , Alberta , Canada , California , San-diego , Spring-house , British-columbia , Horsham , Saskatchewan , Americans